Abstract:Background: Results of initial randomised trials of endovascular treatment for ischaemic stroke, published in 2013, were neutral but limited by the selection criteria used, early-generation devices with modest efficacy, non-consecutive enrollment, and treatment delays. Recent developments: In the past year, six positive trials of endovascular thrombectomy for ischaemic stroke have provided level 1 evidence for improved patient outcome compared with standard care. In most patients, thrombectomy was performed in addition to thrombolysis with intravenous alteplase, but benefits were also reported in patients ineligible for alteplase treatment. Despite differences in the details of eligibility requirements, all these trials required proof of major vessel occlusion on non-invasive imaging and most used some imaging technique to exclude patients with a large area of irreversibly injured brain tissue. The results indicate that modern thrombectomy devices achieve faster and more complete reperfusion than do older devices, leading to improved clinical outcomes compared with intravenous alteplase alone. The number needed to treat to achieve one additional patient with independent functional outcome was in the range of 3·2-7·1 and, in most patients, was in addition to the substantial efficacy of intravenous alteplase. No major safety concerns were noted, with low rates of procedural complications and no increase in symptomatic intracerebral haemorrhage. WHERE NEXT?: Thrombectomy benefits patients across a range of ages and levels of clinical severity. A planned meta-analysis of individual patient data might clarify effects in under-represented subgroups, such as those with mild initial stroke severity or elderly patients. Imaging-based selection, used in some of the recent trials to exclude patients with large areas of irreversible brain injury, probably contributed to the proportion of patients with favourable outcomes. The challenge is how best to implement imaging in clinical practice to maximise benefit for the entire population and to avoid exclusion of patients with smaller yet clinically important potential to benefit. Although favourable imaging identifies patients who might benefit despite long delays from symptom onset to treatment, the proportion of patients with favourable imaging decreases with time. Health systems therefore need to be reorganised to deliver treatment as quickly as possible to maximise benefits. On the basis of available trial data, intravenous alteplase remains the initial treatment for all eligible patients within 4·5 h of stroke symptom onset. Those patients with major vessel occlusion should, in parallel, proceed to endovascular thrombectomy immediately rather than waiting for an assessment of response to alteplase, because minimising time to reperfusion is the ultimate aim of treatment.

Improving Stroke Treatment and Outcomes With Mobile Stroke Units

Endovascular Therapy in Acute Ischemic Stroke: Time is Brain

Endovascular Treatment For Acute Ischemic Stroke: Updates And Future Implications

Mobile Stroke Units: Current and Future Impact on Stroke Care

Improving Outcomes After Stroke: From Stroke Units to Mobile Stroke Units

Mobile stroke care expedites intravenous thrombolysis and endovascular thrombectomy

Endovascular Treatment or General Treatment: How Should Acute Ischemic Stroke Patients Choose to Benefit from Them the Most?

Bringing Emergency Neurology to Ambulances: Mobile Stroke Unit

Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke

Mobile Stroke Units: Bringing Treatment to the Patient

Mobile Stroke Units: Field Imaging and Triage for Acute Stroke Emergencies

Guest Editorial: An Update on Stroke Intervention

Mobile stroke units for prehospital thrombolysis, triage, and beyond: benefits and challenges

Hyperacute ischemic stroke care—Current treatment and future directions

Benefits of stroke treatment delivered using a mobile stroke unit trial

A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Endovascular Thrombectomy Compared with Best Medical Treatment for Acute Ischemic Stroke

Thrombolysis for acute ischaemic stroke: current status and future perspectives

Fifty Years of Acute Ischemic Stroke Treatment: A Personal History

Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries

Endovascular Treatment of Acute Stroke

Endovascular Administration after Intravenous Infusion of Thrombolytic Agents for the Treatment of Patients with Acute Ischemic Strokes